At Therabron Therapeutics, we are working to change how respiratory diseases are managed. We are aiming to not only provide symptomatic relief, but also to improve long-term health outcomes and reduce healthcare costs.  A privately held, clinical-stage, biopharmaceutical corporation, Therabron is developing a new class of drugs from the secretoglobin family of proteins.  Our lead product, recombinant human CC10 protein (rhCC10), is a potent anti-inflammatory agent for patients with respiratory diseases.

Therabron Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein (rhCC10), which has immediate clinical applications in respiratory diseases.Learn More
Therabron Therapeutics holds specialized expertise, reagents, and know-how required for the commercialization of biopharmaceutical products based on the unique and enigmatic secretoglobin family of proteins.Learn More
Experienced biopharmaceutical executives and professionals, the management team and board of directors at Therabron Therapeutics has the technical and business acumen to take the company to the next level.Learn More


Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native CC10 protein in patients.  We are developing a pharmaceutical therapy to replace CC10 with the synthetic version (rhCC10) in respiratory diseases characterized by inflammation and pre-existing CC10 deficiency.


Restoration of CC10 function using rhCC10 has the potential to modify, or even rehabilitate, inflamed airways in diseases like asthma, chronic or recurrent sinusitis, COPD, and pulmonary fibrosis, rather than just treat the symptoms. RhCC10 has completed two Phase 1 clinical trials in which it demonstrated potent anti-inflammatory activity and significant long-term benefit in premature infants, who are known to lack sufficient native CC10 in their lungs.

Therabron Therapeutics, Inc. is a Delaware biotechnology corporation headquartered in Rockville, Maryland.

The Statistics Are Truly Overwhelming

The numbers don’t lie.  Our goal is to improve long-term health outcomes and reduce healthcare costs.

Number of Premature Infants at Risk of BPD Annually
Number of Lives COPD Claims Annually
Americans with Recurrent Acute Sinusitis
Estimated Sufferers from Asthma
Americans Affected by Pulmonary Fibrosis